
Istituto Giannina Gaslini
Istituto Giannina Gaslini
24 Projects, page 1 of 5
Open Access Mandate for Publications assignment_turned_in Project2016 - 2018Partners:CNR, BUU, BIOKERALTY, AVIDIN KTF, SIG +8 partnersCNR,BUU,BIOKERALTY,AVIDIN KTF,SIG,AVIDIN KTF,Istituto Giannina Gaslini,CSIC,BIOKERALTY,Istituto Giannina Gaslini,SIG,BIONEER A/S,UBUFunder: European Commission Project Code: 667079Overall Budget: 4,591,290 EURFunder Contribution: 4,591,290 EURThis project will develop an innovative therapeutic approach for the treatment of Cystic Fibrosis (CF). This condition originates from the defective function of the CFTR protein, a chloride and bicarbonate permeable transmembrane channel. This project will evaluate small molecules capable of facilitating the transmembrane transport of anions such as chloride and bicarbonate and will thus enable CF treatment by replacing the missing CFTR anion permeation activity. This represents an unexplored path in the treatment of CF and a paradigm shift with respect to current strategies searching for a cure for CF. Instead of focusing on the development of mutation-specific treatments, we plan to develop a therapy applicable to CF patients, regardless of the type of mutation they harbor. Thus, this therapeutic approach overcomes the limitation of current mutation-specific treatments and is applicable to CF patients in general. To achieve this goal we have set up a comprehensive program to validate a research concept and complete the preclinical development of a new lead compound, making it ready for early clinical development. A rmultidisciplinary team of qualified researchers have been assembled to bring to conclusion a truly translational project from the synthesis of new compounds to validation on animal models. Cystic Fibrosis affects more people than any other rare disease. Therefore, it could be said, at least in quantitative terms, that CF qualifies as the main target of the topic. This project aims to complete the preclinical development of novel, innovative drugs based on a radically new concept in Cystic Fibrosis therapies. This result fully addresses the expected impact set out in the work programme of advancing the development of new therapeutic options for patients living with rare diseases as well as contributing to reach the IRDiRC objective to deliver 200 new therapies for rare diseases by 2020.
All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda__h2020::04b50455ef8310d90c671d1524d4fdc8&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eumore_vert All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda__h2020::04b50455ef8310d90c671d1524d4fdc8&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euOpen Access Mandate for Publications assignment_turned_in Project2011 - 2015Partners:UCL, deCODE Genetics (Iceland), University of Liverpool, ULB, University of Glasgow +16 partnersUCL,deCODE Genetics (Iceland),University of Liverpool,ULB,University of Glasgow,University of Tübingen,deCODE Genetics (Iceland),RCSI,SEIN,RCSI,SEIN,UL,Istituto Giannina Gaslini,Istituto Giannina Gaslini,Universitäts-Augenklinik Bonn,Belfast Health and Social Care Trust,GABO:mi,UMC,Imperial,GABO:mi,Belfast Health and Social Care TrustFunder: European Commission Project Code: 279062All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda_______::ada4a41c02b7a69d6f6c470f19e17d08&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eumore_vert All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda_______::ada4a41c02b7a69d6f6c470f19e17d08&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euOpen Access Mandate for Publications assignment_turned_in Project2013 - 2018Partners:Universitätsklinikum Erlangen, CNRS, MMED, ULB, VARIONOSTIC GMBH +34 partnersUniversitätsklinikum Erlangen,CNRS,MMED,ULB,VARIONOSTIC GMBH,Charité - University Medicine Berlin,DIVAL,CAU,AMARNA,IIT,Baker IDI Heart and Diabetes Institute,DIVAL,CSIC,University of Angers,OPBG,Istituto Giannina Gaslini,CF consulting Finanziamenti Unione Europea,UCL,UCSC,University of Verona,Istituto Neurologico Carlo Besta,KLINIKUM DER UNIVERSITAET ZU KOELN,University of Malta,KCL,University of Liverpool,INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE,Istituto Giannina Gaslini,Baker IDI Heart and Diabetes Institute,VARIONOSTIC GMBH,LETI,University of Verona,CEGAT GMBH,OPBG,CF consulting Finanziamenti Unione Europea,AMARNA,University of Florence,Universitätsklinikum Erlangen,CEGAT GMBH,KLINIKUM DER UNIVERSITAET ZU KOELNFunder: European Commission Project Code: 602531All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda_______::9015c3a20323f1bd43697141ef971d5b&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eumore_vert All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda_______::9015c3a20323f1bd43697141ef971d5b&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euOpen Access Mandate for Publications and Research data assignment_turned_in Project2024 - 2028Partners:SIOPEN VEREIN ZUR FORDERUNG DER NEUROBLASTOMFORSCHUNG, University of Tübingen, MUI, Istituto Giannina Gaslini, University Hospital in Motol +29 partnersSIOPEN VEREIN ZUR FORDERUNG DER NEUROBLASTOMFORSCHUNG,University of Tübingen,MUI,Istituto Giannina Gaslini,University Hospital in Motol,IMEC,Charité - University Medicine Berlin,PrinsesMaximaCentrumvoorKinderoncologie,AIT,UoA,SIOPE,University Hospital in Motol,UGhent,IMEC,GENIKO NOSOKOMEIO PAIDON ATHINON I AGIA SOFIA,Amsterdam UMC,CHILDREN'S HEALTH IRELAND,CHILDREN'S HEALTH IRELAND,UoA,STICHTING AMSTERDAM UMC,Istituto Giannina Gaslini,PrinsesMaximaCentrumvoorKinderoncologie,SIOPEN VEREIN ZUR FORDERUNG DER NEUROBLASTOMFORSCHUNG,Institut Gustave Roussy,Stichting VU-VUmc,Institute Curie,ESD - EVALUATION SOFTWARE DEVELOPMENT GMBH,ST. ANNA KINDERKREBSFORSCHUNG,GENIKO NOSOKOMEIO PAIDON ATHINON I AGIA SOFIA,VHIR,ESD - EVALUATION SOFTWARE DEVELOPMENT GMBH,ST. ANNA KINDERKREBSFORSCHUNG GMBH,SIOPE,VHIRFunder: European Commission Project Code: 101137028Overall Budget: 7,232,390 EURFunder Contribution: 7,232,390 EURHigh-risk neuroblastoma accounts for 15% of cancer related-deaths in children. Half of the >1500 patients yearly diagnosed with neuroblastoma in the EU have high-risk disease, which will relapse or progress in half these cases after first-line treatment. Relapsed neuroblastoma is aggressive and often therapy-resistant. Monitoring for disease relapse and therapy response is crucial for the survival chance of these patients. The current standard-of-care for monitoring are imaging technologies and bone marrow assessment, which are costly, invasive and a burden for children, who often require anesthesia. These drawbacks limit how often is monitored. More sensitive, less invasive and less toxic monitoring techniques are needed. The mutational spectrum often changes in recurring tumors, which may explain therapy resistance and provide additional druggable targets. Imaging, however, provides no information about molecular characteristics. Liquid biopsy tests are minimally invasive, allow frequent sampling and sensitively detect tumor molecular markers in tumor-derived DNA and messenger RNA circulating in peripheral blood. MONALISA aims to close existing gaps and establish liquid biopsies as standard-of-care to monitor relapsed/refractory neuroblastoma, as a blueprint for other pediatric cancers. Reliable, early assessment of molecular progression or relapse is the main aim of the pragmatic randomized clinical trial proposed in MONALISA. We develop a digital decision support tool to help oncologists use the new monitoring and apply patient-reported outcomes to integrate patient viewpoints and assess the effect of minimally invasive, liquid biopsy diagnostics on quality of life. We will establish whether events can be detected earlier using liquid biopsy monitoring, and whether better overall survival is enabled by earlier diagnosis and treatment interventions. This essential step towards personalized medicine will support reliable disease monitoring under treatment. “This action is part of the Cancer Mission cluster of projects on ‘‘Diagnostics and Treatment (diagnostics).”
All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda_____he::7cf317274e105047d89525f445bbf3f3&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eumore_vert All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda_____he::7cf317274e105047d89525f445bbf3f3&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euOpen Access Mandate for Publications assignment_turned_in Project2010 - 2013Partners:UNIVERSITE PARIS DESCARTES, FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR, UKE, UCL, University of Tübingen +30 partnersUNIVERSITE PARIS DESCARTES,FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR,UKE,UCL,University of Tübingen,University of Manchester,France Europe Innovation,UNIVERSITE D'AUVERGNE,INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE,Istituto Giannina Gaslini,FCSR,Association ELA,UMC-Mainz,France Europe Innovation,OPBG,TROPHOS SA,IDIBELL,Istituto Giannina Gaslini,UMC-Mainz,Soluscience,Istituto Neurologico Carlo Besta,TROPHOS SA,Association ELA,MPG,UNSW,Universitäts-Augenklinik Bonn,THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE,OPBG,IDIBELL,THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE,Université Paris Diderot,Amsterdam UMC,FCSR,Medical University of Vienna,University of Clermont AuvergneFunder: European Commission Project Code: 241622All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda_______::0b2a6339617dd94b988cbd79a5560861&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eumore_vert All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda_______::0b2a6339617dd94b988cbd79a5560861&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eu
chevron_left - 1
- 2
- 3
- 4
- 5
chevron_right